company background image
INVA

Innoviva NasdaqGS:INVA Stock Report

Last Price

US$13.04

Market Cap

US$910.0m

7D

-3.8%

1Y

-22.9%

Updated

27 Nov, 2022

Data

Company Financials +
INVA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

INVA Stock Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally.

Innoviva, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Innoviva
Historical stock prices
Current Share PriceUS$13.04
52 Week HighUS$20.71
52 Week LowUS$11.57
Beta0.59
1 Month Change-3.91%
3 Month Change-2.90%
1 Year Change-22.93%
3 Year Change-3.26%
5 Year Change-1.44%
Change since IPO-28.00%

Recent News & Updates

Innoviva Stock? Not Yet. Short Puts? Definitely.

Sep 19

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Sep 19
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Recent updates

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Sep 19
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Jun 16
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Mar 04
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Oct 19
Is Innoviva (NASDAQ:INVA) A Risky Investment?

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Mar 30
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04
Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15
Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Shareholder Returns

INVAUS PharmaceuticalsUS Market
7D-3.8%1.6%1.3%
1Y-22.9%9.9%-18.5%

Return vs Industry: INVA underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: INVA underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is INVA's price volatile compared to industry and market?
INVA volatility
INVA Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: INVA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: INVA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19965Pavel Raifeldhttps://www.inva.com

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.

Innoviva, Inc. Fundamentals Summary

How do Innoviva's earnings and revenue compare to its market cap?
INVA fundamental statistics
Market CapUS$909.97m
Earnings (TTM)US$292.58m
Revenue (TTM)US$373.22m

3.1x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INVA income statement (TTM)
RevenueUS$373.22m
Cost of RevenueUS$35.17m
Gross ProfitUS$338.05m
Other ExpensesUS$45.47m
EarningsUS$292.58m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.19
Gross Margin90.58%
Net Profit Margin78.39%
Debt/Equity Ratio84.2%

How did INVA perform over the long term?

See historical performance and comparison